Stowasser, Susanne

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 4,654

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 2,403

Nintedanib for systemic sclerosis–associated interstitial lung disease

Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine

Systemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 1,647

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 1,005

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials

Richeldi, L., Cottin, V., du Bois, R. M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., & Brown, K. K. (2016) · Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 463

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial

Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., et al. (2018) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 305

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.

Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., et al. (2025) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 297

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS

Costabel, U., Inoue, Y., Richeldi, L., Collard, H. R., Tschoepe, I., Stowasser, S., & Azuma, A. (2016) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 280

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhosphodiesterase function and regulation

Cited by 236

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials

Lancaster, L., Crestani, B., Hernandez, P., Inoue, Y., Wachtlin, D., Loaiza, L., Quaresma, M., Stowasser, S., & Richeldi, L. (2019) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 209

Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria

Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M. (2017) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 180

Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON

Song, J. W., Ogura, T., Inoue, Y., Xu, Z., Quaresma, M., Stowasser, S., Stansen, W., & Crestani, B. (2020) · Respirology

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 39

No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone

Richeldi, L., Fletcher, S., Adamali, H., Chaudhuri, N., Wiebe, S., Wind, S., Hohl, K., Baker, A., Schlenker-Herceg, R., Stowasser, S., et al. (2019) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacogenetics and Drug Metabolism

Cited by 34

Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial

Maher, T. M., Jenkins, R. G., Cottin, V., Nishioka, Y., Noth, I., Selman, M., Song, J. W., Ittrich, C., Diefenbach, C., Stowasser, S., et al. (2024) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 7